Latest News

Fresh French fund for healthcare

© Grafikplusfoto/fotolia.com


09.09.2016 - iBionext’s healthcare VC fund iBionext Growth has announced a first closing of €46m. All in all, iBionext aims to take in around €100m to reinvest in biotech and medtech companies.

The fund has drawn interest from international investors, insurance companies and family offices, alongside the Biotech & Healthcare Acceleration Fund (FABS) operated by Bpifrance in the context of the Investments for the Future Program (PIA) managed by General Commissariat for Investment (CGI). Created in 2016 as an extension of the iBionext network established in 2012, iBionext Growth Fund is positioned as the missing link in the financing chain of innovative healthcare companies.

Alexia Perouse, CEO & Managing Partner of iBionext, commented: “We are delighted to have generated such momentum around our unique initiative and we thank our investors for the confidence they have placed in us. iBionext operates with a very entrepreneurial approach designed to meet the challenges that innovative healthcare companies can face, from creation to growth, with the goal of creating leaders in their field.”

The most notable creation of the iBionext network was GenSight Biologics, one of the few biotechs to successfully go public this year.

LSP raises a whopping €850m for the European life sciences

LSP 7 is the first European life sciences venture fund to reach a fund size of US$1bn, a “milestone for the industry” stresses LSP. The investment...

BioNTech SE licences Cresendo Bio’s Humabody technology

The three-year collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise including mRNA-based antibodies and cell therapies...

€40m for Treg starver start-up

The Paris-based biotech develops immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases. Egle...

Depixus raises €30.6m in Series A financing

The financing of the spin-out from Paris-based Ecole Normale Supérieure (ENS) was led by Lansdowne Partners and Bpifrance with participation by...

Novartis inks US-$1.3bn deal with Dunad Therapeutics

British start-up company Dunad Therapeutics has signed a collaboration and license agreement with Novartis AG to generate orally bioavailable...

Sofinnova Capital X Fund closed at €472m

The early-stage healthcare venture capital fund, Sofinnova Capital X,was oversubscribed at €472m. This brings the total amount the venture...

Recordati bags EUSA to strengthen rare disease franchise

EUSA Pharma, which focuses on rare and niche oncology diseases, was founded in 2015. The company has a portfolio of four niche oncology products,...